Tag Archives: access to health care

Germany’s Largest Authorized Health Insurance Company Approves MyoPro | Business | Instant News

BOSTON – (BUSINESS WIRE) – February 16, 2021–

Myomo, Inc. (NYSE American: MYO) (“Myomo” or “Company”), a wearable medical robotics company offering enhanced functionality for those with neurological disorders and upper limb paralysis, today announced Techniker Krankenkasse (TK), Germany’s largest Statutory Health Insurance (SHI) company. , now approves MyoPro replacement on a case by case basis. TK covers more than 10 Million lives insured and joins the ranks of other major German health insurance providers including BARMER, IKK Classic, regional AOK insurance and several BKK insurances which collectively cover 28 million German lives and have now approved funding for MyoPro.

About 90% of the German population is covered by SHI providers.

In addition, one of the largest private health insurance companies in Germany, Allianz, has now authorized MyoPro. Private insurance covers about 9% of the population.

Myomo’s Managing Director for Europe, John Frijters, stated, “Many users who have received MyoPro through German insurance experience loss of hand and arm function due to stroke, brachial plexus injury or spinal cord injury. Receiving MyoPro as a result of this insurance decision changed their life. “

In Germany, MyoPro is administered through a growing network of Orthotic and Prosthetic (O&P) clinics across the country. Currently, these 35 facilities serve and support MyoPro users.

Paul R. Gudonis, CEO of Myomo, said, “Our progress in Germany, although now limited by the COVID-19 lockdown, shows us that there is strong and wide-ranging demand for MyoPro. Coupled with the joint venture we recently announced in China, we are working to become the global standard of care for those with paralyzed or weak arms. “

This announcement coincides with the introduction of the new Myomo website in German. These can be found on www.myomo.de.

Myomo, Inc. is a medical robotics company that offers enhanced arm and hand function to those with neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore the function of a weakened or paralyzed arm of a patient who has had a CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only device on the market that, by sensing a patient’s own EMG signal via a non-invasive sensor in the arm, can restore an individual’s ability to perform daily activities, including self-feeding, carrying objects and performing household tasks. Many are able to return to work, live independently, and reduce maintenance costs. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals throughout the US and international representatives. For more information, please visit www.myomo.com.

Forward-looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including the benefits expected from insurance coverage in Germany and our activities in Germany, Australia and China, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forwards are only predictions and may differ materially from actual results due to various factors.

These factors include:

  • our sales and commercialization efforts;
  • our ability to obtain reimbursements from third party payers for our products;
  • our reliance on external sources to finance our operations, to the extent that we do not break even in cash flows;
  • our ability to effectively execute our business plans and improve our operations;
  • our expectations for our development program; and
  • general market, economic, environmental and social factors, including the ongoing COVID-19 pandemic, which may affect the evaluation, installation, delivery and sale of our products to patients.

Further information on these and other factors that could potentially affect our financial results including in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10 -Q and other submissions with the Commission. The company warns readers not to rely too much on forward-looking statements, which only take effect on the date they are made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all the information currently available to us, we cannot guarantee future transactions, results, performance, achievements or results. No guarantee can be made for any investor by anyone that the expectations reflected in our forward-looking statements will be achieved, or that deviations from them will be material and detrimental. The Company disclaims any further obligation to revise forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of events that were anticipated or unexpected.

212-838-3777 Public Relations:



Business Wire Copyright 2021.

PUB: 02/16/2021 08:30 AM / DISC: 02/16/2021 08:30

Business Wire Copyright 2021.


image source

Decades later, Congress restores Medicaid for the Marshall and other Pacific Islanders in the US | National | Instant News

Nearly 25 years ago, with a pen stroke, the United States broke its commitment to provide medical care to Marshall Islanders living in the United States.

Last weekend, congressional negotiators agreed to return the pledge, providing Medicaid protection and the Children’s Health Insurance Program to the tens of thousands of Marshall residents and residents of several other Pacific Island nations living in the United States.

“We are all so excited by the tears of joy for this fight that many of us have been a part of” for decades, said Sheldon Riklon, a Marshall doctor at the Northwest Center University of Arkansas Medical Center. “It is a historic statute that we finally correct the mistakes.”

Health care assistance comes as the COVID-19 pandemic and related job losses have hit many Marshall Islands and Pacific Island communities in the United States, from Washington state to Arkansas.

“The COVID-19 pandemic has shown us terrible health injustices … the whole world is ignoring it,” said Melisa Laelan, executive director of the Arkansas Coalition of Marshallese, in a statement. “Today we find peace and comfort in knowing that one of our human rights will eventually be restored.”

In 1986, the United States and the Republic of the Marshall Islands signed a bilateral agreement allowing Marshallese to enter the United States as “official non-immigrants” in exchange for the US military continuing to operate a weapons testing base at Marshalls. It also provides Marshallese with Medicaid coverage.

A similar agreement, known as the Compacts of Free Association, was signed with the countries of Palau and the Federated States of Micronesia.

Then, in 1996, President Bill Clinton signed a welfare reform bill, which changed the categories of people eligible for federal assistance, including Medicaid – Marshall citizens and other co-citizens of the nation were barred from entry.

Although the residents’ negligence was deemed a mistake, Congress refused to reinstate them – even as several legislators, including Senator Mazie Hirono and US Representative Tulsi Gabbard, both Democrats from Hawaii, pushed for their reinstatement.

Their efforts, and those of others, have now borne fruit.

“This bipartisan agreement will open up new tools to help the COFA community who are suffering from unequal access to health care,” Hirono said in an emailed statement. “By allowing States to register COFA citizens in Medicaid, we are upholding the promises we have made to our important national security partners in Free Related Countries.”

Gabbard noted the bill would also help states like Hawaii, Oregon and Washington, which have stepped in to fill the federal void for compact residents.

The Marshall people “were promised support by the federal government because of the damage done to their health and homes by the nuclear tests,” said Gabbard, who also urged that the nation’s cohesive children be reinstated in the federal school meal program.

Between 1946 and 1958, the United States detonated 67 nuclear bombs on, in and over the Marshall Islands – vaporizing entire islands, carving craters in shallow lagoons and displacing hundreds of people from their homes.

For decades after that, the US continued to use the islands to test biological weapons and conventions. The US still sends missiles to the islands, and Marshall residents who live near the US military base at Kwajalein atoll are used to taking cover, periodically, from incoming missiles from California, or other weapons testing programs.

“This is certainly a great Christmas present for all COFA residents across the US. A very large governance committee for everyone who played a role in bringing us to this milestone,” said Eldon Alik, Consul General of the Republic of the Marshall Islands, Arkansas.

(c) 2020 Los Angeles Times

Distributed by the Tribune Content Agency, LLC.

Copyright 2020 Tribune Content Agency.


image source

Vala Health and Smart Cover Insurance Launches New Health Care Products On Demand | Business | Instant News

LONDON – (Antara / BUSINESS WIRE) – Nov 16, 2020–

Vala Health, a London-based startup that is disrupting the healthcare industry by focusing on the causes, not only has it announced a new partnership with Watford-based Smart Cover Insurance. This new partnership will enable Smart Cover to offer health plans, and GP protection directly to existing and future policyholders.

This press release features multimedia. Check out the full release here: https://www.businesswire.com/news/home/20201115005130/en/

Vala Telemedicine runs on Google Home devices. (Photo: Business Wire)

What we’ve seen this year with Covid, is that most people in the UK live in a ‘health coverage vacuum’ where there are only a few expensive health insurance options that cost more than they can afford. That means many neglect the coverage altogether, “Pete Trainor explains, CEO of Vala.” When we first met Smart-Cover leaders this summer, it became clear immediately that they aim to offer health support to as many audiences as possible, at a price that is not ridiculous, and to a community that needs it. the most.

Smart-Cover and Vala will leverage this unique health care proposition to provide policyholders with access to Vala’s extensive medical network of cover coverage for members and their immediate family, with the aim of helping people ‘stay healthy’ rather than just caring for them, demanding, when they’re sick.

Over the next three months, Vala has some impressive product updates, including epigenetics that will give people complete control over personalized lifestyle adjustments. They also plan to make diet, obstetrics, and Covid-19 rapid antigen tests available to smart-cover audiences.

Vala provides unique GP coverage in three important ways, explains Trainor. ” First, we make it really easy to get doctor appointments on our telemedicine platform. There are no apps to download or complicated processes, you order on the spot, and you’ll speak to a qualified and regulated professional, based in the UK by video or phone. Second, we don’t limit our appointments to a short period of time, or limit the number of appointments a person can have with us during a month. Unlimited. We want people to talk openly about their health issues, and our team will do more than help you in ten minutes and prescribe pills like any other e-doctor platform. Finally, and this is what we focus most on, we want to help people manage their lifestyle choices and take care of them well, rather than making them better when they are sick.

Smart Cover also launched an insuretech home emergency application that extends insurance benefits for health and motor skills. Niraz Buhari, Group CEO, said: ” We invest heavily in technology that will make quality GP consulting more affordable and accessible to many and we found Vala to be the right partner for us because our customer-centric business values ​​align “. He added.” Too many areas of the UK face shortages of doctors and limited access to medical care. Our affordable virtual wellness packages provide easy and free access to Vala doctors to help people make better medical decisions about their overall health in addition to access to specialists and treatments. That’s what health care should be.

For more information on Vala, visit www.valahealth.com

For more information on Smart-Cover, visit www.smart-cover.co.uk

About Vala and Smart-Cover

Vala envisions a world where everyone has understanding and control of their health outcomes with the support of regulated healthcare professionals and smarter technology.

Smart Covers are available in UK. To learn more, visit https://smart-cover.co.uk/gp-service or contact [email protected].

See the source version at businesswire.com:https://www.businesswire.com/news/home/20201115005130/en/

CALL: Pete Trainor, CEO of Vala Health

Niraz Buhari, CEO of Smart Cover Insurance

Phone: 07562 774645

Email: [email protected]



SOURCE: Vala Health

Copyright 2020 Business Wire.

PUB: 11/16/2020 02:00 AM / DISC: 11/16/2020 02:00 AM


Copyright 2020 Business Wire.


image source

Popular Clinical Topics: Cancer and COVID-19 | Instant News

Every week, we identify one top search term, speculate about what caused its popularity, and provide infographics on related conditions. If you have thoughts about what is trending and why, please share with us at Indonesia or Facebook.

News about the prevalence of cancer among patients with COVID-19 and the concerns associated with providing cancer care during a pandemic resulted in the topic of this week’s top trending clinical topics. A meta-analysis published in JCO Global Oncology confirm a previous report that suggested that patients with cancer, and survivors, are an important risk population for COVID-19. The new findings are limited by the retrospective nature of the included studies. The study authors hope that additional data from China and Italy will further clarify the types of cancer associated with a higher risk, as well as treatment regimens that increase complications of COVID-19 infection.

Some cancer patients and COVID-19 registrants has been launched recently. Their aim is to determine the characteristics of patients with cancer who have the most severe COVID-19 infection, as well as the estimated severity of the disease, modification and delay of treatment, and clinical outcomes. The American Society of Clinical Oncology (ASCO) requests practice throughout the country to share information about their patients for educational purposes. Information collected through a web-based registry will not be available for commercial purposes. This contradicts data collection conducted by CancerLinQ, a wholly owned subsidiary of ASCO. CancerLinQ has been criticized to enable partner companies to sell access to their data without asking for patient permission.

Patients with cancer that are not infected with COVID-19 are still affected by a pandemic. A survey conducted by the American Cancer Society Cancer Action Network found that almost a quarter (24%) of respondents experienced delays in care or care. Sadder, 12% reported that their treatment was not only postponed, but they also have not been notified when the treatment will be rescheduled. Cancer experts report the difficulties they face in trying to continue to provide the care that their patients need. Many are turning to solutions like telemedicine and other virtual health services. These strategies are among the suggestions given by the author a Special feature articles in Journal of the National Comprehensive Cancer Network . Their list of 10 recommendations includes screening, telemedicine, and restrictive procedures. This article also provides guidelines for the best way to ensure the safety of health workers while providing cancer care during a crisis.

Management of lung cancer during the COVID-19 crisis is a special problem. Experts in Europe issue recommendations intended to minimize the risk of patients infected with SARS-CoV-2 while hospitalized. The author suggests that personalized care must be emphasized. This includes evaluating the possible benefits of treatment and the possibility of delaying surgery. New global registry (TERAVOLT) has been launched to collect data that will be used to develop risk assessment strategies tailored for patients with lung cancer. The author emphasizes that the international consensus on COVID-19 testing in lung cancer is very important to achieve that goal.

The crossover between COVID-19 and cancer is complex and ongoing. When more recommendations and data are available, subjects tend to remain among the top trending clinical topics.

Read more clinical information about COVID-19.


image source